IRVINE, CA--(Marketwired - Sep 19, 2017) - Cannabis Science, Inc. (
"Nanoparticle drones to target lung cancer with radiosensitizers and cannabinoids," addresses drug delivery, and highlights an innovative strategy to transport cannabinoids directly to cancer cells with minimal toxicities or side effects that have so far hampered clinical translation efforts. The article is an initial result of burgeoning CBIS collaborative work and speaks to a key conclusion from the National Academies of Sciences, Engineering, and Medicine 2017 Report on "The health effects of cannabis and cannabinoids: Current state of evidence and recommendations for research."
The Article In Full can be accessed for your reading here:
Received: 27 June 2017; Accepted: 24 August 2017;
Published: 19 September 2017
Keywords: smart nanoparticles (drones), radiotherapy, radiosensitizers, cannabinoids, inhalation, intravenous delivery, lung cancer, therapeutic efficacy
Citation: Ngwa W, Kumar R, Moreau M, Dabney R and Herman A (2017) Nanoparticle Drones to Target Lung Cancer with Radiosensitizers and Cannabinoids. Front. Oncol. 7:208. doi: 10.3389/fonc.2017.00208
John Varlotto, University of Massachusetts Medical Center, United States
Wenyin Shi, Thomas Jefferson University, United States
Shiv K. Gupta, Mayo Clinic Minnesota, United States
"The laboratory work from CBIS' collaborations are moving apace and more results are to be reported soon," stated Mr. Raymond C. Dabney, Cannabis Science Inc., President & CEO, Co-Founder. Currently, early results show that using smart drug-delivery systems to deliver cannabinoids directly to tumor cells leads to increased tumor cell kill in animal models of lung and pancreatic cancer, which are some of the deadliest cancers. These results are also being prepared for presentation at upcoming national and international conferences.
The innovative drug delivery strategy for cannabinoids is consistent with the three primary elements in Cannabis Science's drug development program: (1) Defining the effectiveness and specificity of cannabinoids being tested; (2) Identifying and testing drug delivery mechanisms; and (3) Testing and evaluating the impact of co-interventions, and the application of additional diagnostic and/or therapeutic procedures to participants in randomized controlled trials. The Company's initial results point to the importance of drug delivery systems and the impact of co-interventions.
"This publication reflects our initial work and we are assiduously working on using our drug delivery system to examine the effect of cannabinoids with and without radiation therapy on lung and pancreatic cancer. This work will form part of our applications to the FDA. As we continue this work we will expand our pharmaceutical development program from farm to bedside," said Allen A. Herman, MD, Ph.D. Cannabis Science Inc., Chief Medical Officer (CMO).
"The field of cannabinoids is expanding rapidly and there are several models of drug development being proposed. We believe that our program that combines the agricultural disciplines of effective and efficient growing of hemp and cannabis; the careful quality assured way of extracting active cannabinoids; and providing these cannabinoids to our scientists to conduct both laboratory and clinical studies presents a robust approach to cannabinoid development," concludes. Mr. Dabney.
About Cannabis Science, Inc.
Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS- NEURO-1, respectively.
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company is detailed from time to time in the company's reports filed with the Securities and Exchange Commission.